Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusheng Qu

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 2004
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic propertiesNarender R Gavva, Rami Tamir, Yusheng Qu, et al.
The Journal of Biological Chemistry|March 5, 2004
Molecular determinants of vanilloid sensitivity in TRPV1Narender R Gavva, Lana Klionsky, Yusheng Qu, et al.
Regulatory Toxicology and Pharmacology : RTP|June 27, 2020
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fractureJames R Turk, Aimee M Deaton, Jun Yin, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
JCI Insight|March 26, 2020
Cardiovascular response to small-molecule APJ activationBrandon Ason, Yinhong Chen, Qi Guo, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 2004
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic propertiesNarender R Gavva, Rami Tamir, Yusheng Qu, et al.
The Journal of Biological Chemistry|March 5, 2004
Molecular determinants of vanilloid sensitivity in TRPV1Narender R Gavva, Lana Klionsky, Yusheng Qu, et al.
Regulatory Toxicology and Pharmacology : RTP|June 27, 2020
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fractureJames R Turk, Aimee M Deaton, Jun Yin, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
JCI Insight|March 26, 2020
Cardiovascular response to small-molecule APJ activationBrandon Ason, Yinhong Chen, Qi Guo, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 3